Refine by
Drug Industry Articles & Analysis
26 news found
DDC is an annual event that gathers researchers, scientists, and experts from across the globe who are involved in the dynamic field of drug discovery. DDC builds a perfect bridge for thought-sharing and networking, reputed to be a must-attend conference for everyone in the drug discovery industry. ...
The screening of substrates, inhibitors, and other ligands is a pivotal facet of enzyme research, enabling scientists to pinpoint compounds best suited for a variety of applications, from drug development to industrial processes. A profound understanding of enzyme-molecule interactions can pave the way for groundbreaking therapies, improved bioprocessing, and the ...
Recently, the company introduced a series of state-of-the-art services in Drug Design and Computer-Aided Drug Design (CADD) with the aim of providing efficient and reliable solutions for the pharmaceutical industry's drug development endeavors. Drug Design is a crucial discipline in pharmaceutical research that ...
Wang Xinlun, Vice President and Secretary-General of China Association for STD and AIDS Prevention and Treatment, industry experts and representatives of partner companies and institutions attended the ceremony. ...
The company's risk-sharing partnership offerings allow organizations to co-develop new drugs using BIOiSIM™ and, hence, predict translation from bench to bedside, reduce R&D costs, lower the risk of selecting new drug candidates, and condense the development time for promising drugs. According to Aarti Chitale, a Frost & Sullivan ...
Technologies like our unique Translational Index™, which synthesizes the potential for clinical success of any drug candidate, enable smarter decisions about how to advance drug asset programs and ultimately improve the lives of patients in ...
The potential applications are subject to the requisite clinical and regulatory commercialization processes. The global psychedelic drugs market is expected to gain significant market growth in the forecast period from 2022 to 2029. ...
Choosing the most appropriate delivery system has tremendous benefits, including but not limited to controlled release of drugs, enhanced drug targeting, improved solubility and bioavailability of drugs. In the past decade, several new drug delivery systems have been formulated, in the hope to provide promising alternative routes ...
The poster spotlights the results of the company’s SIGHT-1 Phase 2a clinical study and its inclusion in this meeting confirms the high level of interest in the eye care industry in drug delivery contact lenses. The SIGHT-1 study demonstrated the safety and tolerability of the company’s lead asset, LL-BMT1, a weekly medicated contact lens releasing ...
VeriSIM offers unprecedented value for the drug development industry by reducing the number of drug compounds likely to treat or cure specific illnesses and diseases. ...
CD BioSciences, a leading customer-focused biotechnology company based in New York, recently introduces a series of GPCR Drug Discovery services to customers in their GPCR drug discovery and development projects. ...
Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer. ...
1 Establishment of new drug pipeline with bilirubin platform technology Securing global competitiveness by increasing corporate value “I want to give hope to those who are living a difficult life with an incurable disease” [IB Tomato Lim Seong-ji] “The new drug development industry is a specialized area that is difficult for ...
[IB Tomato Reporter Lim Seong-ji] “The new drug development industry is a specialized area that is difficult for general investors and shareholders to understand, and it is difficult to deliver accurate information even when publicly available. The bad examples of some companies that have been inflated even with content are hindering the development of the ...
(known as MSD outside of the United States and Canada) to evaluate the combination of Evaxion’s cancer immunotherapy EVX-01 with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a new Phase 2b clinical trial in patients with metastatic melanoma Awarded this year’s Enabling Technology Leadership Award in the artificial intelligence-enabled drug discovery ...
Daniel Motto, Enalare's Chief Operating Officer, will highlight how the successful partnership with BARDA is accelerating the development of Enalare's lead drug candidate ENA-001 as a potential treatment for respiratory depression in both mass casualty situations and the drug overdose epidemic. BARDA Industry Day has grown into a premier annual ...
Nob Hill Therapeutics' Executive Chairman Paul Atkins will be presenting at the Partnership Opportunities in Drug Delivery (PODD) conference during the DryNeb – Advancing Pulmonary Drug Delivery session on Friday, October 29th at 12:00pm ET. PODD is an annual virtual event where members of the pharma, biotech and drug delivery ...
It is very rewarding to see that this value is being recognized more and more by drug developers. What industry trends are most exciting right now? ...
To advance cell therapy development and commercialization, Thermo Fisher announced a collaboration with the University of California, San Francisco (UCSF) on a 44,000-square-foot, state-of-the-art cell therapy development, manufacturing and collaboration center on UCSF's Mission Bay campus. Broadening Industry-Leading Drug Product Development and Steriles ...
Ariana, a leading eXplainable Artificial Intelligence (AI) drug development company, is delighted to announce the appointment of Dr. ...